Navigation Links
New oral agents may prevent injury after radiation exposure
Date:7/10/2009

(Boston) Researchers from Boston University School of Medicine (BUSM) and collaborators have discovered and analyzed several new compounds, collectively called the ''EUK-400 series,'' which could someday be used to prevent radiation-induced injuries to kidneys, lungs, skin, intestinal tract and brains of radiological terrorism victims. The findings, which appear in the June issue of the Journal of Biological Inorganic Chemistry, describe new agents which can be given orally in pill form, which would more expedient in an emergency situation.

These agents are novel synthetic "antioxidants" that protect tissues against the kind of damage caused by agents such as "free radicals." Free radicals, and similar toxic byproducts formed in the body, are implicated in many different types of tissue injury, including those caused by radiation exposure. Often, this kind of injury occurs months to years after radiation exposure. The BUSM researchers and their colleagues are developing agents that prevent injury even when given after the radiation exposure.

This paper describes a newer class of compounds, the ''EUK-400 series,'' that are designed to be given as a pill. According to the researchers, experiments described in their paper prove that these agents are orally active. They also show that the new agents have several desirable "antioxidant" activities, and protect cells in a "cell death" model.

These same BUSM researchers and collaborators had previously discovered novel synthetic antioxidants that effectively mitigate radiation injuries, but had to be given by injection. "We have developed some of these agents and have studied them for over 15 years beginning with our work at the local biotechnology company Eukarion," said senior author Susan Doctrow, PhD, a research associate professor of medicine at BUSM's Pulmonary Center. "These injectible antioxidants are very effective, but there has also been a desire to have agents that can
'/>"/>

Contact: Allison Rubin
allison.rubin@gmail.com
617-638-8490
Boston University Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Is 4 agents decoction (Si Wu Tang) efficacious in treating primary dysmenorrhea?
2. Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
3. ABR-Affinity BioReagents Expands 100% Quality Guarantee
4. Inside job: new radioactive agents for colon cancer work inside cells
5. ABR -- Affinity BioReagents Announces Launch of New Website
6. EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference
7. Controversial physical agents directive postponed
8. Health Insurance Agents Warn Against Imposing a Health Care Reform Tax in California
9. ABR-Affinity BioReagents Announces Its Continued Support for the Society for Neuroscience Annual Meeting in San Diego, November 3 - 7, 2007
10. Benepath Launches Exclusive Marketing Service for Health Insurance Agents and Agencies
11. National Patient Advocate Foundation (NPAF) Statement Regarding New FDA Label on Erythropoietin Stimulating Agents (ESAs)

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...tlinker.comannouncesthatanewmarketresearchreportis...arketTrends ,, http://www.reportlinker.com/p...m_source=prnewswire&utm_medium=pr&utm_camp...uchasSARS,outbreakoffluandbioterrorismhavefurthere...entingthespreadofinfections.Allthesefactorshavecon...
(Date:11/23/2009)...the November issue of GIE: Gastrointestinal Endos...l of the American Society for Gastrointestinal End...found that Barrett,s esophagus was detected in six...ic screening. Also in this issue, two studies exam... France, in the largest single-center experience t...
(Date:11/23/2009)...eorgia is leading an initiative that could result ...ickle cell disease. , Morehouse University Scho...ers in the initiative that is enlisting primary ca...homes" for patients, changing how patients are tre... and seeking better prevention and treatment strat...
(Date:11/23/2009)... been a simple case for a New York auto accident a...arge. , New York (PRWEB) ...or New York auto accident attorneys passed to cr...e turned fatal., , , , ,According to the New Yor...hot and killed during a heated road-rage argument....
(Date:11/23/2009)...re/--XiotechCorporationtodayannouncedthatMasonGene...ragesystem,poweredbyIntelligentStorageElement(ISE(...,enablefuturegrowthanddeliversignificantcapitaland..., MasonGeneral,locatedinShelton,Wash.,wasratedone...ed-Rural"hospitalsin2008and2009foritssuperioruseof...
Breaking Medicine News(10 mins):Health News:Reportlinker Adds Hand Sanitizers - US Market Trends 2Health News:Reportlinker Adds Hand Sanitizers - US Market Trends 3Health News:Reportlinker Adds Hand Sanitizers - US Market Trends 4Health News:Study highlights from November issue of GIE: Gastrointestinal Endoscopy 2Health News:Study highlights from November issue of GIE: Gastrointestinal Endoscopy 3Health News:Study highlights from November issue of GIE: Gastrointestinal Endoscopy 4Health News:Study highlights from November issue of GIE: Gastrointestinal Endoscopy 5Health News:Initiative could result in paradigm shift in the care of sickle cell patients 2Health News:Initiative could result in paradigm shift in the care of sickle cell patients 3Health News:Initiative could result in paradigm shift in the care of sickle cell patients 4Health News:Initiative could result in paradigm shift in the care of sickle cell patients 5Health News:An Incident of Road Rage Turns Into Murder 2Health News:ISE Technology by Xiotech Helps Hospital Achieve Data Center Efficiency, Savings 2
...xhaustive study on suicide has revealed that suici...n in spring or summer//. Researchers analyz... and 2001 in England and Wales, and revealed that ...e pronounced amongst women, who showed a 30% likel...
...ung men treat their erection problems with erectil...iption. // These results were revealed after an an...ago universities. The research was led by Naja...es’ annual meeting. It revealed that about 95 perc...
... lift her surveillance zone for wild birds as plan...was found to have the lethal H5N1 strain of bird f...ing the spread of the deadly bird flu virus in Sco...Fife. The Scottish Executive had introduced ...
... smoking in Scotland, it would stop sales of tobac...itted to buy it. Ministers have not decided ...ikely to do so, given Jack McConnell's determinati...ing is far worse than drinking. I am in favour of ...
...published, figures for rates of serious bloodstrea...step is taken to assure// the public that all meas...o protect the public. John Wardell, 76, a former ...hiteside, from Rhyl, along with the group MRSA Sup...
... American Journal of Medicine has found that estro...levels of the female// sex hormone increase the ri...who had low levels of both estrogen and testostero...al Heart, Lung and Blood Institute's Framingham He...
Other Medicine News:Health News:Young Men Treating Erection Problems without Doctors Prescription 2Health News:Hip Fracture Risk Increases In Men Having Low Estrogen Levels 2
(Date:11/23/2009)...ov.23/PRNewswire-FirstCall/--WoundManagementTechno...providerofspecialtymedicalproducts,announcedthatit...prehensivemanagementbusinessupdatetoillustratethed...9salesincreased33.5%to$102,926vs.Q32008salesof$77,...dto$3,327,892vs.Q32008shareholderequityof$(321,257...
(Date:11/23/2009)...v.23/PRNewswire-FirstCall/--Pharmasset,Inc.(Nasdaq...edbyitspartnerRoche(SWX:ROG.VX;RO.S,OTCQX:RHHBY),w...intheongoingphase2btrialofRG7128,afirst-in-classnu...chronichepatitisCvirus(HCV)infection.Thedecisionwa...nitoringCommittee(DMC)ofallavailablesafetydatafrom...
(Date:11/23/2009)...ZER,Pa.,Nov.23/PRNewswire-FirstCall/--CeptionThera...y,andCephalon,Inc.(Nasdaq: CEPH )todayannouncedres...eslizumab)asatreatmentforpediatriceosinophilicesop...entintheco-primaryendpointsofchangesinesophagealeo...aindicatedthatpatientstreatedwithCINQUILshowedasta...
Breaking Medicine Technology:Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 2Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 3Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 4Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 5Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 2Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 3Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 4Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis 2Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis 3Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis 4Shamir Optical Industry Ltd Reports Second Quarter 2009 Results 54429 1Shamir Optical Industry Ltd Reports Second Quarter 2009 Results 54429 2Shamir Optical Industry Ltd Reports Second Quarter 2009 Results 54429 3Shamir Optical Industry Ltd Reports Second Quarter 2009 Results 54429 4Shamir Optical Industry Ltd Reports Second Quarter 2009 Results 54429 5Shamir Optical Industry Ltd Reports Second Quarter 2009 Results 54429 6Shamir Optical Industry Ltd Reports Second Quarter 2009 Results 54429 7Shamir Optical Industry Ltd Reports Second Quarter 2009 Results 54429 8Shamir Optical Industry Ltd Reports Second Quarter 2009 Results 54429 9Shamir Optical Industry Ltd Reports Second Quarter 2009 Results 54429 10Impact of cannabis on bones changes with age study finds 54427 1Interventional radiology treatment for uterine fibroids 3A Safe nonsurgical option 54424 1Interventional radiology treatment for uterine fibroids 3A Safe nonsurgical option 54424 2Interventional radiology treatment for uterine fibroids 3A Safe nonsurgical option 54424 3
...ansdel,Pharmaceuticals, Inc. (OTC Bulletin Board: ...and Drug Administration,s ("FDA") review of its Ph...e 3 clinical program for its,novel topical cream b...),Ketotransdel(TM). Transdel Pharmaceuticals is a ...lopment and commercialization of non-invasive,topi...
...ular Structures Needed for siRNA ...8 Silence Therapeutics plc,(AIM:SLN) Europe,s lea...ments on two recent journal articles: Nature(1) "S...ssion by siRNA via TLR3" Mark E.,Kleinman, et. al....,siRNA/Liposome Complexes in Mice is Sequence-Inde...
Other Medicine Technology:Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program 2Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program 3Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach 2Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach 3Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach 4
SMZ-660
SMZ-645
SMZ-1500
Achroplan Wasser objectives
Medicine Products: